LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Kodu・Aktsiate loetelu・Bio-Techne Corp

Bio-Techne Corp

Avatud

Sektor Tervishoid

70.67 0.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

69.5

Max

70.97

Põhinäitajad
By Trading Economics
Sissetulek	-8.5M 41M
Müük	-303B 306M
P/E Sektori keskmine	50.64 112.16
Aktsiakasum	0.49
Kasumimarginaal	13.26
EBITDA	92M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.92 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024
Järgmine dividendimakse kuupäev	22. nov 2024
Järgmine aktsia dividendi kuupäev (ex-date)	7. nov 2024

Turustatistika
By TradingEconomics
Turukapital	-972M 11B
Eelmine avamishind	70.22
Eelmine sulgemishind	70.67

Uudiste sentiment

By Acuity

77%

23%

358 / 389 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

69.93 / 71.24 Toetus ja vastupanu

Bio-Techne Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2024, 23:02 UTC

Peamised uudised

Australian Consumer-Confidence Recovery Still Intact Amid Building Rate-Cut Hopes

28. okt 2024, 23:01 UTC

Suurimad hinnamuutused turgudel

Lithium Americas Shares Rise After News of DOE Loan

28. okt 2024, 22:40 UTC

Tulu

Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26

28. okt 2024, 22:29 UTC

Tulu

Waste Management Posts Revenue Growth on Price Increases

28. okt 2024, 23:52 UTC

Peamised uudised

McDonald's Finds an Unlikely Savior to Finally Fix Its McFlurry Machines -- Update

28. okt 2024, 23:42 UTC

Market Talk

Lithium Spodumene Prices Have Likely Bottomed -- Market Talk

28. okt 2024, 23:07 UTC

Peamised uudised

McDonald's Finds an Unlikely Savior to Finally Fix Its McFlurry Machines -- WSJ

28. okt 2024, 23:00 UTC

Tulu

WuXi AppTec 3Q Rev CNY10.46B, Down 2% on Year >603259.SH

28. okt 2024, 22:59 UTC

Tulu

WuXi AppTec 3Q Net CNY2.29B , Down 17% on Year >603259.SH

28. okt 2024, 22:15 UTC

Tulu

Sandfire Resources Net Debt $345 Million at End-Sept

28. okt 2024, 22:15 UTC

Tulu

Sandfire Resources 1Q Underlying Ebitda $121 Million

28. okt 2024, 22:15 UTC

Tulu

Sandfire Resources 1Q Unaudited Sales Revenue $282 Million

28. okt 2024, 22:14 UTC

Tulu

Sandfire Resources 1Q Underlying Operating Cost of $78/Ton of Ore Processed at Matsa Operation

28. okt 2024, 22:14 UTC

Tulu

Sandfire Resources 1Q Underlying Operating Cost of $40/Ton of Ore Processed at Motheo Operation

28. okt 2024, 22:13 UTC

Tulu

Sandfire Resources Says Copper Equivalent Output at Matsa Operation Up 4% in 1Q

28. okt 2024, 22:13 UTC

Tulu

Sandfire Resources Reaffirms FY 2025 Output, Cost, Capex Guidance

28. okt 2024, 22:12 UTC

Tulu

Sandfire Resources 1Q Silver Output 1.3 Million Oz, Up 9% on Quarter

28. okt 2024, 22:12 UTC

Tulu

Sandfire Resources 1Q Lead Output 2,081 Tons, Up 9% on Quarter

28. okt 2024, 22:12 UTC

Tulu

Sandfire Resources 1Q Zinc Output 21,542 Tons, Down 1% on Quarter

28. okt 2024, 22:11 UTC

Tulu

Sandfire Resources 1Q Copper Output 27,012 Tons, Down 1% on Quarter

28. okt 2024, 22:11 UTC

Tulu

Sandfire Resources 1Q Copper Equivalent Output 38,000 Tons, Flat on Quarter

28. okt 2024, 22:07 UTC

Tulu

China Southern Airlines: Strong Travel Demand Supported Results >1055.HK

28. okt 2024, 22:07 UTC

Tulu

China Southern Airlines 9-Mos Rev CNY134.66B Vs. CNY119.49B >1055.HK

28. okt 2024, 22:07 UTC

Tulu

China Southern Airlines 9-Mos Net CNY1.97B Vs. Net CNY1.32B >1055.HK

28. okt 2024, 22:01 UTC

Tulu

CMOC Group: Higher Income From Mining and Processing Segment Supported Results >3993.HK

28. okt 2024, 22:00 UTC

Tulu

CMOC Group 3Q Rev CNY51.94B, Up 15.5% on Year >3993.HK

28. okt 2024, 21:59 UTC

Tulu

CMOC Group 3Q Net CNY2.86B , Up 64.1% on Year >3993.HK

28. okt 2024, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Fomento Economico Mexicano to Sell Plastics Solutions Operations to AMMI for MXN3.17B

28. okt 2024, 21:23 UTC

Tulu

Waste Management Raises 2024 Revenue View to Up 6% >WM

28. okt 2024, 21:21 UTC

Tulu

Waste Management 3Q Adj EPS $1.96 >WM

Võrdlus sarnastega

Hinnamuutus

Bio-Techne Corp Prognoos

Hinnasiht

By TipRanks

16.92% tõus

12 kuu keskmine prognoos

Keskmine 82.29 USD 16.92%

Kõrge 95 USD

Madal 65 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Bio-Techne Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Bio-Techne Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

69.93 / 71.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

358 / 389 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.